Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewRuBi-caged dopamine (Cat. No. 3548); exhibits two-photon sensitivity. Enables non-invasive, optical activation of dopamine receptors with the spatial resolution of a single dendritic spine. Does not display phototoxicity at a concentration of 300 μM.
Sold under licence from Columbia University
分子量 | 713.6 |
公式 | C31H36Cl2N5O2PRu |
储存 | Store at -20°C |
PubChem ID | 90488992 |
InChI Key | FPJFHIJODNWCIM-UHFFFAOYSA-L |
Smiles | [Cl-].[Cl-].[Ru++].CP(C)C.NCCC1=CC=C(O)C(O)=C1.C1=CN=C(C=C1)C1=CC=CC=N1.C1=CC=C(N=C1)C1=CC=CC=N1 |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
参考文献是支持产品生物活性的出版物。
Araya et al (2013) Two-photon optical interrogation of individual dendritic spines with caged DA. ACS Chem. Neurosci. [Epub ahead of print] PMID: 23672485
关键词: RuBi-Dopa, RuBi-Dopa supplier, caged, dopamine, two, photon, sensitive, sensitivity, microscopy, dopaminergic, neurons, high, resolution, dendritic, spines, Non-selective, Dopamine, Caged, Compounds, 4932, Tocris Bioscience
目前没有该产品的评论。 Be the first to review RuBi-Dopa and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。
Written by Phillip Strange and revised by Kim Neve in 2013, this review summarizes the history of the dopamine receptors and provides an overview of individual receptor subtype properties, their distribution and identifies ligands which act at each receptor subtype. Compounds available from Tocris are listed.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.